Jyothi P. Jagannathan

Major Response to Imatinib Mesylate in <i>KIT</i>-Mutated Melanoma

F. Stephen Hodi, Philip Friedlander, Christopher L. Corless et al. · Journal of Clinical Oncology · 2008 · 414 citations · Full text

Medicine, Oncology, Pathology +17

Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know

Mizuki Nishino, Jyothi P. Jagannathan, Nikhil H. Ramaiya et al. · American Journal of Roentgenology · 2010 · 379 citations

Medicine, Oncology, Radiology +12

Metastatic Pattern of Bladder Cancer: Correlation With the Characteristics of the Primary Tumor

Atul B. Shinagare, Nikhil H. Ramaiya, Jyothi P. Jagannathan et al. · American Journal of Roentgenology · 2010 · 272 citations

Medicine, Oncology, Pathology +15

Ipilimumab associated hepatitis: imaging and clinicopathologic findings

Kyung Won Kim, Nikhil H. Ramaiya, Katherine M. Krajewski et al. · Investigational New Drugs · 2013 · 233 citations

Medicine, Immunology, Pathology +12

Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Min‐Hee Ryu, Changhoon Yoo et al. · The Lancet Oncology · 2013 · 186 citations

Medicine, Oncology, Pharmacotherapy +11